Abbott Laboratories (NYSE:ABT) received an FDA warning letter focused on the accuracy and testing of its FreeStyle Libre ...

Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found.

Boone Health said Abbott has been assisting with the redistribution of new monitors Freestyle Libre 3 and 3 Plus since recall.

ETHealthworld.com brings latest abbott laboratories news, views and updates from all top sources for the Indian Health industry.

Add Yahoo as a preferred source to see more of our stories on Google. FreeStyle Libre 3 sensor by Abbott Image by Adobe Medical device giant Abbott announced on Sunday that it is recalling ...

Certain glucose monitors from Abbott Diabetes Care are providing users with incorrect glucose readings, an error that has been linked with the deaths of at least ...

Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to ...

Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the ...

Abbott (NYSE:ABT) is facing an FDA warning letter alleging quality system regulation violations related to FreeStyle Libre CGM production.